Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Core Viewpoint - Cardiol Therapeutics Inc. is participating in Canaccord Genuity's 45th Annual Growth Conference, highlighting its focus on developing therapies for heart disease [1][2]. Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart disease [3]. - The company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is in clinical development and aims to treat heart disease by inhibiting the inflammasome pathway [3][4]. Clinical Development - Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [4]. - The MAVERIC Program focuses on recurrent pericarditis, with a completed Phase II study and an ongoing Phase III trial [4]. - The completed ARCHER trial is a Phase II study in acute myocarditis, a significant cause of heart failure in young adults [4]. Additional Drug Development - Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation for heart failure, which is a leading cause of death and hospitalization, with healthcare costs in the US exceeding $30 billion annually [5].